Lv1
20 积分 2023-06-08 加入
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
7个月前
已完结
Targeting HER2-positive breast cancer: advances and future directions
7个月前
已完结
HER2-targeted therapies - a role beyond breast cancer
7个月前
已完结
HER2 and Breast Cancer - A Phenomenal Success Story
7个月前
已完结
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
7个月前
已完结
皖公网安备34019202002308
